Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2018, Article ID 8721753, 9 pages
https://doi.org/10.1155/2018/8721753
Clinical Study

AC-CUTE: An Open-Label Study to Evaluate Progression of Structural Joint Damage and Inflammation in Subjects with Moderate to Severe Rheumatoid Arthritis

1University of New South Wales, Sydney, NSW, Australia
2Combined Rheumatology Practice, Kogarah, NSW, Australia
3Spire Sciences, Inc., Boca Raton, FL, USA
4Barwon Rheumatology Service, Geelong, VIC, Australia
5Roche Products Pty, Limited (Australia), Sydney, NSW, Australia
6Royal Prince Alfred Hospital, Camperdown, NSW, Australia
7Cabrini Medical Centre, Malvern, VIC, Australia

Correspondence should be addressed to Paul Bird; ua.moc.hcraesersumitpo@dribp

Received 13 November 2017; Revised 13 February 2018; Accepted 26 February 2018; Published 12 April 2018

Academic Editor: Tim Jansen

Copyright © 2018 Paul Bird et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Kremer, R. Blanco, M. Brzosko et al., “Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year,” Arthritis & Rheumatology, vol. 63, no. 3, pp. 609–621, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Dougados, K. Kissel, T. Sheeran et al., “Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY),” Annals of the Rheumatic Diseases, vol. 72, no. 1, pp. 43–50, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. P. G. Conaghan, C. Peterfy, E. Olech et al., “The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: Results from the ACT-RAY MRI substudy,” Annals of the Rheumatic Diseases, vol. 73, no. 5, pp. 810–816, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. G. R. Burmester, A. Rubbert-Roth, and A. Cantagrel, “A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study),” Annals of the Rheumatic Diseases, vol. 73, no. 1, pp. 69–74, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Choy, R. Caporali, R. Xavier et al., “FRI0215Subcutaneous Tocilizumab as Monotherapy or in Combination with A csDMARDs in Patients with Rheumatoid Arthritis – Interim Analysis of A Large Phase IV International Umbrella Study, “Tozura”,” Annals of the Rheumatic Diseases, vol. 75, no. Suppl 2, pp. 509.2–510, 2016. View at Publisher · View at Google Scholar
  6. F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis & Rheumatism, vol. 31, no. 3, pp. 315–324, 1988. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Aletaha, T. Neogi, A. J. Silman et al., “2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative,” Arthritis & Rheumatology, vol. 62, no. 9, pp. 2569–2581, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. H. K. Genant, “Methods of assessing radiographic change in rheumatoid arthritis,” American Journal of Medicine, vol. 75, no. 6, pp. 35–47, 1983. View at Publisher · View at Google Scholar · View at Scopus
  9. H. K. Genant, Y. Jiang, C. Peterfy, Y. Lu, and et al., “Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs,” Arthritis & Rheumatism, vol. 41, no. 9, pp. 1583–1590, 1998. View at Publisher · View at Google Scholar
  10. M. Østergaard, C. Peterfy, P. Conaghan et al., “OMERACT rheumatoid arthritis magnetic resonance imaging studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system,” The Journal of Rheumatology, vol. 30, no. 6, pp. 1385-1386, 2003. View at Google Scholar · View at Scopus
  11. C. G. Peterfy, J. C. DiCarlo, E. Olech, M.-A. Bagnard, A. Gabriele, and N. Gaylis, “Evaluating joint-space narrowing and cartilage loss in rheumatoid arthritis by using MRI,” Arthritis Research & Therapy, vol. 14, no. 3, article no. R131, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Lassere, M. Boers, D. Van Der Heijde et al., “Smallest detectable difference in radiological progression,” The Journal of Rheumatology, vol. 26, no. 3, pp. 731–739, 1999. View at Google Scholar · View at Scopus
  13. D. Cella, S. Yount, M. Sorensen, E. Chartash, N. Sengupta, and J. Grober, “Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis,” The Journal of Rheumatology, vol. 32, no. 5, pp. 811–819, 2005. View at Google Scholar · View at Scopus
  14. M. Tamai, K. Arima, Y. Nakashima et al., “Baseline MRI bone erosion predicts the subsequent radiographic progression in early rheumatoid arthritis patients who achieved sustained good clinical response,” Modern Rheumatology, vol. 27, no. 6, pp. 961–966, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Sewerin, S. Vordenbaeumen, A. Hoyer et al., “Silent progression in patients with rheumatoid arthritis: is DAS28 remission an insufficient goal in RA? Results from the German Remission-plus cohort,” BMC Musculoskeletal Disorders, vol. 18, no. 1, pp. 1–9, 2017. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Beals, R. Baumgartner, C. Peterfy et al., “Magnetic resonance imaging of the hand and wrist in a randomized, double-blind, multicenter, placebo-controlled trial of infliximab for rheumatoid arthritis: Comparison of dynamic contrast enhanced assessments with semi-quantitative scoring,” PLoS ONE, vol. 12, no. 12, Article ID 0187397, 2017. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Peterfy, M. C. Genovese, E. Keystone et al., “Magnetic resonance imaging substudy in a phase 2b dose-ranging study of baricitinib, an oral janus kinase 1/janus kinase 2 inhibitor, in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis,” Arthritis Rheum, vol. 64, p. S1050, 2012. View at Google Scholar
  18. C. Peterfy, V. Strand, L. Tian et al., “Short-Term changes on MRI predict long-Term changes on radiography in rheumatoid arthritis: An analysis by an OMERACT Task Force of pooled data from four randomised controlled trials,” Annals of the Rheumatic Diseases, vol. 76, no. 6, Article ID annrheumdis-2016-210311, pp. 992–997, 2017. View at Publisher · View at Google Scholar · View at Scopus